Evidence supports metformin as a first-line agent to treat type 2 diabetes, according to a study in the online edition of the Annals of Internal Medicine.
Evidence supports metformin as a first-line agent to treat type 2 diabetes, according to a study in the online edition of the Annals of Internal Medicine.
Investigators from Johns Hopkins University School of Medicine in Baltimore and other centers determined that metformin, both as monotherapy and in combination with other medications, has the highest benefit-risk profile in most comparisons with other medications for diabetes.
Two reviewers, working independently, identified 140 trials and 26 observational studies of head-to-head comparisons of monotherapy or combination therapy that reported intermediate or long-term clinical outcomes or harms. The investigators found that most diabetes medications were similarly efficacious when used as monotherapy and decreased HbA1c levels by 1 absolute percentage point on average. However, metformin proved superior to dipeptidyl peptidase-4 (DPP-4) inhibitors in reducing HbA1c. Combination therapy, including that of metformin and DPP-4 inhibitors, decreased HbA1c levels more than monotherapy did - by approximately 1 absolute percentage point.
There was a 4-fold higher risk of mild-to-moderate hypoglycemia associated with sulfonylureas compared to use of metformin alone; the risk increased to 5-fold when sulfonylureas were combined with metformin compared to a metformin-plus-thiazolidinediones combination. In addition, metformin decreased low-density lipoprotein cholesterol levels significantly compared to pioglitazone, sulfonylureas, and DPP-4 inhibitors. Most diabetes medications generally increased weight. Metformin, however, was consistently associated with weight reduction or was neutral.
Patients taking thiazolidinediones had an increased risk for congestive heart failure compared with those taking sulfonylureas and an increased risk for bone fractures compared to metformin. Diarrhea occurred more often in patients taking metformin than in those taking thiazolidinediones.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.